oNKo-037

oNKo-037 is a preclinical-stage drug candidate developed by oNKo-innate Pty Ltd. It functions as an IL-15 modulator, specifically by targeting and ablating negative regulators of IL-15 signaling in Natural Killer (NK) cells. This genetic modification, often achieved through CRISPR-based functional genomic screens, leads to enhanced NK cell proliferation, increased release of pro-inflammatory cytokines, and improved NK cell cytotoxicity. By alleviating NK cell immunosuppression and boosting IL-15 signaling, oNKo-037 aims to improve NK cell fitness and anti-tumor immunity, positioning it as a potential immunotherapy for neoplasms.